Expanding the scope of our ambitions
As part of Crucell’s corporate strategy, The Crucell Ambition, we are working hard to translate our commitment to corporate social responsibility (CSR) into action. In our efforts to further improve global health worldwide, developing our CSR performance and reporting are key priorities for Crucell in the coming years. In the following sections we highlight our standards for doing business in a responsible way.
A pivotal year
Crucell has made important progress in developing its approach to corporate social responsibility (CSR). In 2009 we made the transition from the ambition to focus more on CSR performance and transparency, to a strategy for how to do this. We also created the basic framework necessary for embedding a CSR program in the organization.
A global CSR policy, focusing on the four themes of Performance, People, Planet and Philanthropy, has been outlined. Key performance indicators, ambitions and targets have been defined for each category, and construction of a centralized data management infrastructure is underway. Top-level ownership of the CSR program will support the continuous development of this approach in the years ahead.
This chapter describes where Crucell now stands in terms of CSR performance, where we are heading and how we plan to get there.
The information in this chapter covers the entire organization for the year 2009 unless otherwise stated. Crucell has not sought external verification of the information in this chapter as our current priority is to complete implementation of our systems for CSR information management and reporting.
CSR highlights in 2009
- Crucell made great progress towards a global, evidence-based system for systematic CSR development and reporting.
- Crucell formulated concrete ambitions and targets in the CSR categories of performance, people, planet and philanthropy.
- Crucell was listed on the Dow Jones Sustainability Index (September 2009).
- Ronald Brus was named biotech CEO of the year at the international Vaccine Industry Excellence Awards.
- Crucell and Johnson & Johnson signed a landmark agreement based on Crucell’s unique capabilities for healthcare innovation; the billion-euro deal provides an enormous boost for these capabilities.
- Crucell started introducing the FlexFactory®, a revolutionary approach to manufacturing. Substantial reductions in pipeline development times and production costs (for new products) are expected.
- Crucell professionalized its procurement organization, thereby laying the foundation for responsible supply chain management.
- Crucell launched ‘Footprint’, its own outreach program. The program will bring Crucell employees and people in disadvantaged communities together, in ways that benefit both groups.